Management of Patients with Liver Transplantation in ICU by Karapanagiotou, Areti et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Management of Patients with 
Liver Transplantation in ICU
Areti Karapanagiotou, Achillefs Pitsoulis, Maria Vasileiou  
and Nikolaos Voloudakis
Abstract
Liver transplantation constitutes the most effective and indispensable treatment 
of end-stage liver disease (ESLD). Major advances in surgical techniques, anesthe-
siological management, postoperative care, immunosuppression, and diagnostic 
approach have led to increased overall survival of patients. Postoperative care poses a 
great challenge since detrimental occurrences that need prompt treatment may affect 
the graft or distant organ functionality. Adequate graft function is strongly associated 
with distant organ restoration and rapid patient recovery. In the ICU setting, the main 
focal points are hemodynamic stabilization, coagulation and electrolyte disturbances 
correction, respiratory support, early weaning from mechanical ventilation, and 
evaluation of graft functionality. It is of paramount importance to facilitate early graft 
recovery, recognize and promptly treat systematic complications and life-threatening 
sequelae, and individualize treatment protocols considering graft quality, donor’s and 
recipient’s health status, and potential co-morbidities. To achieve those goals, techno-
logical advancements in continuous patient monitoring, graft functionality, and its 
metabolic reserves must be assimilated and implemented in the ICU.
Keywords: liver transplantation, post-liver transplantation intensive care,  
immediate postoperative management, complications, infections prophylaxis,  
early postoperative complications
1. Introduction
In the past years, liver transplantation (LT) has made leaps and evolved from an 
endeavor in specialized centers to a worldwide definitive and gold standard treat-
ment of the end-stage liver disease (ESLD), acute liver failure, and various cancer 
types [1, 2].
The advances in perioperative management, including the improvement of 
surgical techniques, preservation solutions, perioperative management, and 
monitoring, as well as advances in immunosuppression and postoperative care have 
led not only to an increased number of transplantations but also to better outcomes 
[2]. According to recent studies in the United Kingdom, the 1- and 5-year survival 
rate for liver transplant recipients has reached 92 and 80%, respectively [3]. 
However, there are still certain challenges in LT. Scarcity of allografts and dispar-
ity between supply and demand has led the transplantation community to expand 
the donor pool by utilizing split grafts, allografts from living donors after cardiac 
death and including marginal donors of older age and with extended steatosis [4]. 
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Additionally, recipients are sicker, given that priority of graft allocation is based on 
higher MELD scores, older and with co-morbidities such as metabolic syndrome, 
cardiac disease, and diabetes mellitus [5, 6]. Postoperative liver transplant patient 
care requires careful accounting of the recipient’s pre-existing pathophysiology, 
intraoperative events, and donor’s quality. Moreover, the implanted liver represents 
a unique biological entity that has undergone physiological changes and has to adapt 
to a new environment. This donor-recipient interaction is the key of a successful 
transplantation [7].
The intensivist’s role is essential as a multifaceted approach is critical for optimal 
transplantation outcomes. The main hurdles to tackle are early recognition and 
immediate treatment of the hemodynamic and metabolic disorders, restoration of 
intravascular volume, avoidance of coagulation disorders, optimization of organs 
function affected by hepatic failure, prophylaxis and treatment of infections, early 
enteral nutrition, and evaluation of graft function. Technological advances offer the 
possibility of continuous cardiovascular and allograft function monitoring facilitat-
ing improved endpoint results.
2. General principles
The aim of immediate postoperative support is the adequate O2 supply to tissues 
and graft by ensuring hemodynamic stabilization, fluid balance, restoration of 
diuresis, optimal ventilation, and supporting graft function. It should be noted that 
graft recovery depends primarily on the intrinsic hepatocyte recovery capacity and 
secondly on optimizing liver hemodynamics and preventing venous stasis.
3. Hemodynamic stabilization and monitoring
The primary goal of hemodynamic monitoring is to prevent inadequate cardiac 
filling and the subsequent tissue hypoperfusion, and also to avoid overloading 
leading to congestion of the lungs and sinusoids and hence allograft dysfunction 
[8]. The intravascular volume, cardiac output (CO), and systematic vascular 
resistance (SVR) are important parameters vital in determining the success of 
a LT. The treatment becomes even more complicated when renal and/or heart 
failure, portopulmonary hypertension, or hepatopulmonary syndromes are also 
present [9].
Successful management of patients with end-stage liver disease (ESLD) requires 
a complete understanding of their hemodynamic profile that is often characterized 
by high cardiac output (CO) with decreased systemic vascular resistance, depleted 
intravascular volume, and compensatory tachycardia with concomitant renal vaso-
constriction and dilutional hyponatremia, due to excessive production of vasodila-
tors during the development of hepatic failure [10]. Following LT, vasodilation and 
hyperdynamic circulation remain until the graft begins to function and excretes 
excess vasodilatory agents that are almost completely restored after 6 months [11].
Upon the arrival of a liver transplant recipient in the ICU, advanced monitoring, 
which estimates CO and volume status, additionally to standard hemodynamic 
monitoring, that is electrocardiogram, pulse-oximetry, and invasive blood pressure, 
are deemed essential [12].
Hemodynamic depression may be the result of hypovolemia, prolonged reperfu-
sion syndrome, cardiac dysfunction, either caused by pre-existing or emerging 
ischemic cardiomyopathy, and metabolic disorders such as acidosis, hypocalcaemia, 
hypothermia, vasodilation due to sepsis, or graft dysfunction.
3Management of Patients with Liver Transplantation in ICU
DOI: http://dx.doi.org/10.5772/intechopen.89435
The assessment of the intravascular volume is of vital importance given that 
volume status can be affected by contradictory factors such hypovolemia or hyper-
volemia, both detrimental for graft and patient survival. Restoring volume status, 
a continually dynamic parameter, and achieving optimal CO are crucial in order 
to maintain the delicate balance between preload optimization and avoidance of 
pulmonary edema [13].
Hypovolemia, possibly due to continued bleeding, occult or overt, inadequate 
fluid replacement and/or loss in the third space, can lead to reduced preload and CO 
and hence hypoperfusion resulting in additional lesions in the newly transplanted 
liver [14]. The aim is to replace the intravascular fluid and maintain the circulat-
ing blood volume. There is still controversy over the type of fluids administered, 
with crystalloids gaining ground against the colloids (hydroxyl ethyl starches), 
which have been associated with renal injury and increased mortality in criti-
cally ill patients [15], a conclusion that is not supported by convincing evidence in 
LT. Nevertheless, the appropriate crystalloid should be carefully selected taking into 
account its special characteristics and based on its metabolism, electrolyte com-
position, pH and osmolarity, and considering patients’ status [16]. Albumin (Alb) 
administration as a replacement fluid has been a matter of debate. In some centers, a 
large amount of Alb is exogenously administered following the LT to support circula-
tory stability. Moreover, a concentration of 25 g/L is considered necessary for the 
immunosuppressive drugs to be effective [17]. Beneficial properties were attributed 
to Alb in recent studies; whereas, postoperative hypoalbuminemia has been linked to 
the development of acute kidney injury (AKI) [18]. It has been found that during LT 
there is translocation of Alb, probably to the interstitial space, which persists until 
the third postoperative day and whose role has not been clearly clarified [19]. Certain 
centers choose to replace two-thirds of the required fluids with crystalloids and 
one-third of drain losses with albumin [14]. Although, blood and blood products 
transfusion strategies vary between institutions, it is considered that postopera-
tive hematocrit (Hct) values, ranging between 25 and 30%, are safe for adequately 
transporting O2 to the new graft [14]. The rational use of blood products depends on 
the monitoring of the coagulation mechanism. Whole-blood viscoelastic tests, such 
as thromboelastogram (TEG) and rotational thromboelastometry (ROTEM), that 
illustrate each step of thrombus formation and fibrinolysis are useful tools to guide 
transfusions and drug administration (anti-fibrinolytics, coagulation factors) [20, 
21] by limiting the number of transfusions, as there has been an association between 
them and increased morbidity/mortality, prolonged stay in the hospital, postopera-
tive sepsis, increased risk of acute rejection, and hepatic artery thrombosis [22–24].
Hypervolemia occurs either from intraoperative over-resuscitation or coexistence 
of renal dysfunction. It can result in capillary leak syndrome with loss of fluids in the 
third space, further congestion and graft edema due to vascular permeability disor-
der, caused by ischemia/reperfusion injury (I/R) that is more pronounced in grafts 
with higher preservation injury, greater steatosis, or in older donors [7, 25]. Studies 
also indicate that massive administration of fluids and blood is a risk factor for com-
plications of the respiratory system postoperatively and is correlated with increased 
mortality [26]. On the contrary, conservative resuscitation strategy and negative 
fluid balance during the first three postoperative days, if hemodynamic stability has 
been achieved, act protectively. Codes et al. [27] concluded that a continuous positive 
balance in the first 4 days after surgery correlates with the development of ΑΚΙ and 
the need for renal replacement therapy (RRT). Goal directed therapy (GDT) strategy, 
which has been successfully applied in major surgical interventions, is proposed. 
It aims at maintaining an adequate supply of O2 to the end organs by a bundle of 
measures including fluid titration in conjunction with blood transfusions as well 
as administration of vasopressors and/or inotropic agents [28]. The hemodynamic 
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targets are predefined and specific variables are used to control fluid adequacy, 
improvement of CO, and tissue perfusion. GDT has beneficial effects compared to 
liberal fluid administration, reducing postoperative ileus, mechanical ventilation 
time, and respiratory system complications, as it has been indicated in relevant, 
although limited, studies [29]. Jiang et al. [30] suggests the individualization of fluid 
administration in the perioperative period as an optimal recovery strategy. They 
estimated that transfusions >100 ml/kg and fluid balance ≤−14 ml/kg during the first 
postoperative days result in prolonged mechanical ventilation, extubation time, and 
ICU stay. Prudent use of vasopressor agents is proposed since they increase arterial 
tone and improve perfusion pressure avoiding overload. Noradrenaline (0.01–1 μg/
kg/min) with mixed α-β-adrenergic effects is most commonly administered to 
maintain CO and organ perfusion. Vasopressin (0.5–0.6 U/h) and terlipressin (1.5 μg/
kg/h) have also been used in recent years because of their modifying effect on visceral 
circulation, where approximately 37% of the total blood volume is located in cirrhotic 
patients, and of their ability to reduce pressure in the portal vein [31, 32].
Since there has been no consensus on hemodynamic monitoring in LT yet, there 
is a number of invasive and noninvasive CO monitors available in order to evaluate 
hemodynamic fluctuations (Table 1) [13, 36].
The pulmonary artery (PAC) catheter has traditionally been used for hemo-
dynamic monitoring in LT. It provides the possibility of measuring the CO by the 
thermodilution method, which is considered the gold standard, but also the cardiac 
Monitors Principle Advantages Limitations
PAC Thermodilution Accurate continuous 
measures of CO
Direct measures of PAP 
and RVEDVI
Gold standard in POPH
Invasive
CVP, PCWP static 
pressures measurement
Unreliable indicators of 
volume status, SV and 
fluid responsiveness
PiCCO Pulse contour 
analysis
Less invasive
Continuous CO, SV 
measures
ITBVI, EVLWI, PPV, 
SVV
Reliable indicators of 
fluid responsiveness
Need for recalibration in 
marked changes of SVR
Inaccurate CO measures in 
Child-Pugh Band C stages 
in cirrhosis
Requires sinus rhythm and 
certain ventilator setting
LiDCO Pulse contour 
analysis
Continuous CO, SV 
measures comparable to 
PAC measures
PPV, SVV
Indicative of volume 
status
Calibration with lithium
Inaccurate CO measures in 
Child-Pugh Band C stages 
in cirrhosis
FlowTrac/Vigileo Pulse contour 
analysis
No need for calibration
Continuous CO, SV 
measures
PPV, SVV, indicative of 
volume status
Not reliable in 
hyperdynamic circulation 




Direct visualization of 
cardiac function and 
volume status
Advanced training is 
required
Risk of rupture in 3rd or 
4th grade of esophageal 
varices
Table 1. 
Hemodynamic monitoring in LT.
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filling pressures, the CVP, and especially the PCWP for assessing the preload [33]. 
Numerous studies have shown that static preload measurements are indirect mark-
ers of the end diastolic volume and have a poor predictive value for fluid manage-
ment, improvement of hepatic perfusion, and recovery guidance [34]. Although 
still under debate, current data favor the use of a modified pulmonary artery cath-
eter, with an incorporated heating coil, that provide continuous measurement of 
CO (CCO) and right ventricular end diastolic volume (RVEDV) as the more reliable 
preload indicator. Patients with portopulmonary hypertension are highly benefited 
from PAC, as it is the method of choice for measuring and monitoring pulmonary 
artery pressures intraoperatively and directly postoperatively [13, 35].
In recent years, interest has shifted to the dynamic parameters and expanding 
data yielded from existing monitoring of blood pressure to assess the CO, the pre-
load and the afterload. There is technology available to accurately analyze pressure 
waveforms and sufficient knowledge to generate algorithms that are interpreted by 
the complex pulse wave morphology [36, 37].
The PiCCO system (Pulsion Medical System, Munich, Germany) uses the 
method of transpulmonary thermodilution, single indicator technique, and arterial 
pulse contour analysis which by means of an algorithm can continuously calculate 
CO and preload markers: global end diastolic volume (GEDVI), extra vascular lung 
water index (EVLWI), and intrathoracic blood volume index (ITBVI) which is con-
sidered a reliable preload indicator in LT. In transplant patients, the CO measure-
ments deriving from the PiCCO system are consistent with those of PAC [38, 39].
Furthermore, this system offers the capability of functional hemodynamic 
monitoring by detecting the changes in left ventricular pulse volume caused by 
changes in preload due to mechanical ventilation. Stroke volume variation (SVV) 
and pulse pressure variation (PPV) have been used successfully to assess the 
intravascular volume and fluid responsiveness in critically ill patients [12, 13, 40]. 
Certain LT studies have concluded that the SVV is a better indicator for RVEDVI 
than CVP, while a SVV greater than 9% is an indicator of low RVEDVI which means 
fluid responsiveness [41, 42]. However, there are always limitations deriving from 
the presence of arrhythmia and mechanical ventilation settings.
The LiDCO system (LiDCO Plus, Cambridge, United Kingdom) is similar to the 
PiCCO system, but in its case the lithium indicator dilution technique is applied in 
order to calibrate the arterial waveform analysis algorithm [40].
The Flowtrac/Vigileo system (Edwards Lifesciences, Irvine, CA United States) 
is a special energy converter that links the arterial line with a CO monitor and uses 
arterial waveform analysis with an algorithm for real-time CO measurement in 
conjunction with patient demographics without the need for calibration. However, 
a poor correlation has been found between findings of waveform analysis CO when 
compared to PAC thermodilution, mainly in patients with cirrhosis B and C accord-
ing to Child-Pugh classification [43, 44]. Biais et al. came to the same conclusion, 
using the recent third generation, FloTrac system, pointing out that there was great 
discrepancy in cases of significantly low SVR [45, 46].
In recent years, the use of transesophageal echocardiography (TEE) has been gain-
ing ground not only because it is considered a noninvasive method, but also because 
it provides the ability to directly visualize the contractility of the left and right heart, 
preload status, and differential diagnosis of various pathological conditions such as 
pulmonary embolism, pleural, or pericardial effusion [47]. The CO can be estimated 
with measurements of flow across the cardiac valve, left ventricular outflow tract, or 
the flow in the main pulmonary artery. The ability to instantly display real-time preload 
is considered its biggest advantage. The functional application of TEE is limited by the 
risk of rupture of the third or fourth grade esophageal varices, but it is considered a reli-
able hemodynamic monitoring method when used by experienced intensivists [12, 13].
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4. Liver allograft function
Assessment of graft function is necessary and is performed by combining 
clinical parameters, laboratory values, and imaging examinations. The first posi-
tive signs of adequate function of the new liver can be evident by the correction of 
metabolic acidosis, coagulation disturbances, hemodynamic stabilization, and tem-
perature normalization in addition to diuresis restoration. Continuous monitoring 
in the postoperative period is required for the immediate recognition of early, subtle 
findings of graft dysfunction which necessitate aggressive treatment. Traditionally, 
the evaluation of liver function involves static and dynamic tests [48].
Static tests include hematology, coagulation, and biochemistry blood tests, in 
order to evaluate the main liver functions. The hepatic enzymes aspartate ami-
notransferase (AST) and alanine aminotransferase (ALT), which rather indicate 
hepatocyte necrosis, display a rise postoperatively reaching their peak during the 
first 2 days before they finally start decreasing. Their elevation is attributed to pres-
ervation injuries and/or prolonged cold ischemia time (CIT). A persisting elevated 
value raises concerns about liver function and requires further investigation. The 
canalicular enzymes γ-glutamyl transferase and alkaline phosphatase increase after 
day four and usually five-fold before their decline begins. The synthetic function 
of the liver is evaluated by the prothrombin time or international normalized ratio 
(INR), which estimate the production of coagulation factors by the liver. Bilirubin 
levels define the liver excretory function while its metabolic function is assessed by 
glucose and lactate levels. A resistant to the treatment hypoglycemia is an indicator 
of graft dysfunction. The levels of lactates should also be carefully considered, if 
increased, due to the fact that such result may derive from peripheral tissue hypoxia.
The dynamic tests express the ability of the liver to metabolize or excrete certain 
substances. The lidocaine conversion to monoethylglycinexylidide metabolite 
(MEGX test) assesses the metabolic capacity and the liver blood flow [48, 49].
The indocyanine green (ICG) clearance test is routinely used in several centers. 
The functional activity of the graft is assessed by ICG dye administration, which is 
almost exclusively eliminated from the liver into the bile without undergoing entero-
hepatic circulation. Its removal from the blood depends on the hepatic blood flow, 
parenchymal cell function, and biliary excretion. It is expressed as half-life time, 
blood clearance, or plasma disappearance rate (ICG-PDR) smaller than 15% associ-
ated with a higher rate of primary dysfunction [50]. The bedside ultrasound imaging 
methods with hepatic blood vessel Doppler examination are usually performed on 
the day of surgery or on the first postoperative one in order to evaluate the patency of 
the hepatic artery, the portal vein, and the hepatic vein. It is particularly useful in the 
presence of intraoperative technical difficulties or when there is graft dysfunction, 
with a view to identify vascular abnormalities that could be treated [51].
Recovery of the graft is a combination mainly of the severity of the recipient’s condi-
tion, donor quality, intraoperative events, perioperative hemodynamic stability, and 
preservation injuries, while adequate blood flow to the organs and prevention of venous 
stasis in the new liver have to be ensured (Table 2) [49]. On the other hand, the risk of 
poor outcome is increased in case of ESLD-associated syndromes and co-morbidities 
coexistence, especially in sicker patients, as estimated by the MELD score [4, 7].
Donor quality has a major impact on the graft function since the use of marginal 
donors is now commonplace [4]. The prolonged time of cold ischemia for more 
than 12 h increases ischemia reperfusion injuries. Macrosteatosis greater than 30% 
reduces tolerances in such injuries, while the risk of rejection and PNF is increased. 
Grafts from donors older than 60 years of age are considered to be of higher risk 
for PNF or exhibit delayed recovery mainly owing to cholestasis, whereas grafts 
from donors older than 75 show reduced liver regeneration capacity [52–54]. 
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Nevertheless, the results in the literature are contradictory; and in 2016, the donors 
older than 65 years old reached a percentage of 20.7%. In a recent study, Gilbo et al. 
concluded that older grafts can be safely used in older recipients without endanger-
ing their survival, if the remaining risk factors have been minimized [55]. The best 
practice for graft allocation is the use of scores that include donor and recipient 
data, such as the survival outcomes following liver transplantation (SOFT) and/or 
the BAR-score, which offer excellent prognostic ability for survival after transplan-
tation and could lead to the final decision on using or rejecting the graft [56].
5. Ventilatory support and weaning from mechanical ventilation
The intraoperative use of short-acting anesthetics and neuromuscular blocking 
agents allows a prompt recovery of consciousness and facilitates the rapid release 
from mechanical support and early extubation (EE), which can occur in the operat-
ing theater or within the first three postoperative hours and is associated with shorter 
ICU and hospital stay. In a recent meta-analysis comparing early versus conventional 
extubation, the authors report a reduction in re-intubation rate, morbidity, respira-
tory complications, incidence of graft dysfunction, and ICU/hospital stay [57–59]. In 
a study published by Taner et al., it was exhibited that early extubation failed only in 
1.90% of patients when performed on selected cases. According to these researchers, 
patients with HCC and low MELD score are appropriate candidates for EE [60].
Prolonged mechanical ventilation (MV) remains a critical risk factor for infec-
tions development, especially ventilator-associated pneumonia, tracheal trauma, 
prolongation of neuromuscular recovery, graft venous congestion due to positive 
intrathoracic pressures, and reduced venous return to the inferior vena cava and 
hepatic veins [61, 62]. It has also been correlated by Yuan et al. with the recipient’s 
age, female gender, preoperative need for renal replacement therapy (RRT), ascites, 
higher MELD score, prolonged cold ischemia, and the number of transfusions [62].
Emphasis is placed on the fact that optimal selection criteria and timing of EE 
have not been clearly defined yet. Patients with encephalopathy, marked hypox-
emia, obesity (BMI > 30), severe hemodynamic instability, pulmonary edema, car-
diac or renal dysfunction, and multiple transfusions are not indicated for EE. The 
personalized and selective approach is likely to be the best strategy with a focus on 
avoiding delayed extubation, preserving hemodynamic stabilization, and ensuring 
graft functionality [63].
The criteria of weaning from MV applied to liver transplanted patients in ICU 
conform to those of the rest patient groups [64]. Distinct sequelae may often arise 



























Graft inflow (Right HF, Hepatic 
vein stenosis/thrombosis)
Graft outflow (Hepatic artery 
and portal vein patency)
Small-for-size syndrome
Table 2. 
Factors related to graft function.
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from ESLD-related disorders such as encephalopathy, massive transfusions, graft 
dysfunction, preoperative nutrition disorders, volume overload, and postopera-
tive respiratory complications including pulmonary edema, pleural effusions, or 
pneumonia. During MV, lungs and liver allograft interaction should be taken into 
account with the aim of improving oxygenation without impairing the outflow 
of the liver graft. Implementation of daily withdrawal of sedation combined with 
spontaneous breathing trial facilitates weaning from MV [63].
Acute respiratory distress syndrome (ARDS), one of the prominent respiratory 
complications following LT, is usually attributed to reperfusion syndrome, substan-
tial blood loss and transfusions, prolonged operation time, and early postoperative 
infections and sepsis. Lung-protective ventilator strategies with low tidal volumes 
(6 ml/kg IBW), higher respiratory rate, and positive end-expiratory pressure 
(PEEP) are recommended to limit lung injury from shear forces and atelectasis 
[64]. There is debate about optimum PEEP in LT since some consider that higher 
PEEP values impair venous return and visceral blood flow leading to hepatic edema. 
Evaluation of transpulmonary pressure has been proposed to optimize PEEP titra-
tion [65]. Saner et al. concluded that PEEP up to 15 cm H2O affects neither blood 
flow to the liver, nor flow and velocity in the hepatic artery, right hepatic vein, and 
portal vein [66]. In refractory ARDS and persistent hypoxia, prone positioning, 
high frequency ventilation, and extracorporeal membrane oxygenation support 
have been utilized as rescue therapy [67–69].
There are certain syndromes related to ESLD characterized by severe hypoxemia 
which require special management in the ICU such as hepatopulmonary syndrome 
and portopulmonary hypertension.
Hepatopulmonary syndrome is caused by intrapulmonary capillary dilatation 
that leads to hypoxemia and shortness of breath. LT is considered the treatment of 
choice; however, in most cases, severe hypoxemia might persist for a 6–12 months 
period. In the ICU, fluids should be managed carefully and lung-protective strate-
gies should be employed during MV. In persistent hypoxemia, high frequency 
ventilation and/or venovenous extracorporeal membrane oxygenation is recom-
mended. Some authors suggest early extubation and the immediate application of 
noninvasive ventilation with high-inspired fraction of oxygen [70, 71].
Portopulmonary hypertension resulting from pulmonary vasoconstriction due 
to portal hypertension requires prevention of hypoxemia, maintaining oxygen 
saturation >90% and correcting factors involved such as acidemia, arrhythmia, and 
anemia. Administration of diuretics and/or renal replacement therapy is advised if 
volume overload cannot be avoided. MV can both compromise venous return from 
the allograft and increase pulmonary vascular resistance through alveolar overdisten-
sion; therefore, lung-protective ventilation is considered to be the most appropriate 
strategy. The use of pulmonary vasodilators, that can be both administered IV such as 
epoprostenol and orally, via nasogastric tube, such as phosphodiesterase V inhibitor or 
nonselective endothelin receptor antagonist, is recommended during ICU stay [71].
6. Immunosuppression
Advances in immunosuppression have greatly impacted the survival of patients 
following LT. The initial endpoint was to prevent rejection; but in recent years, the 
interest has also been shifted to avoiding long-term complications from immuno-
suppressant agents and relapsing of the disease. In spite of the latest developments 
in this field, most centers commence immunosuppression with calcineurin inhibi-
tors (CNIs) and corticosteroids with or without an anti-proliferative agent depend-
ing on protocols [72, 73].
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Calcineurin inhibitors: Tacrolimus and cyclosporine inhibit calcineurin by 
impairing interleukin-2 (IL-2) transduction. Used as first-line immunosuppressant, 
tacrolimus is considered 100 times more potent than cyclosporine, and is supe-
rior in graft and patient survival with fewer acute and steroid-resistant rejection 
episodes. The main side effect is nephrotoxicity, while hypertension, hyperkale-
mia, uremic hemolytic syndrome, and neurotoxicity have lesser incidence [72]. 
Corticosteroids are important both in the initial immunosuppressive therapy and in 
the treatment of acute rejection.
Mycophenolate mofetil has been widely used as an adjuvant and alternative 
immunosuppressive agent. It is a potential inhibitor of B- and T-cell proliferation. It 
is mainly utilized when a dose reduction or discontinuation of CNI is demanded due 
to certain adverse effects such as nephrotoxicity and neurotoxicity [72].
Mammalian target of rapamycin (mTor) inhibitors, sirolimus, and everolimus, 
prevent B- and T-cell proliferation prompting the cell to arrest at G1 to S phase of 
the cell cycle. Although accounted for wound healing delay incidents, they can be 
administered as primary and rescue immunosuppression therapy with the advan-
tages of being renal sparing as well as reducing the need for high doses of steroids. 
The newer IL-2 receptor-blocking antibody preparations daclizumab (Zenapax) 
and basiliximab (Simulect) are often used to initiate immunosuppression and avoid 
CNIs, and can also play a part in steroid-resistant rejection [72].
7. Infection prophylaxis
Prevention of infections is a major problem as they are the leading cause of death 
following LT [74]. The most common ones in the immediate postoperative period 
are of bacterial or fungal origin and include bloodstream, catheter related, surgical 
site, pulmonary, urinary tract, Clostridium difficile infections, and intra-abdominal 
collections. The identification of risk factors and the stratification of patients 
according to them determine the prophylactic perioperative antimicrobial treat-
ment [75, 76]. Antimicrobial chemoprophylaxis depends on the patient’s immune 
status, intraoperative events, recent or recurrent hospitalization, and donor infec-
tions at the time of liver graft procurement while it has been tailored in accordance 
with the colonization of the patients, recently characterized by a prevalence of 
multidrug-resistant Gram-negative bacilli [76, 77]. Other recipient-related risk 
factors are malnutrition, re-operation, acute liver failure, biliary complications, 
and the existence of postoperative catheters, lines, and drains. Antibiotics right 
before surgery cover Gram-negative bacteria (Pseudomonas sp., Enterobacter sp., and 
Klebsiella sp.), Gram-positive organisms (Staphylococcus aureus), fungi, and viruses 
according to the center protocols and their epidemiology. Antifungal prophylaxis 
is administered to higher risk patients determined by factors such as renal dysfunc-
tion with a need for RRT, re-transplantation, multiple transfusions, prolonged ICU 
stay, colonization by Candida, and graft rejection incidents with administration of 
high doses of corticosteroids. In many centers, azoles or liposomal amphotericin are 
used [76–78]. Siddique et al. reported that the rate of post-transplant infections was 
24.5% with no difference between deceased and living donors; however, mortality 
was higher in bacterial infections in deceased donor recipients [79].
Herpes family viral infections, due to immunosuppression mainly by 
administration of T-cell-specific agents, are adequately treated with acyclovir. 
Ganciclovir or valganciclovir is sufficient for CMV seronegative recipients with 
CMV-seropositive grafts, or after rejection treatment. In case of suspected infection 
during hospitalization, broad spectrum antimicrobial therapy is administered and 
reviewed according to cultures results [75].
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8. Nutritional support in liver transplant recipients
Post-LT nutritional support in ICU is an essential adjunct to transplant recovery. 
Malnutrition, which characterizes many patients with ESLD being evident at rates of 
up to 80%, deteriorates with the progression of liver failure, and affects the patients’ 
outcome [80]. On the other hand, it is associated with prolonged ICU and hospital stay, 
infections, respiratory complications, graft impairment, and mortality. Sarcopenia, 
defined as severe muscle wasting, is also a determining factor of the outcome, and it 
can be easily diagnosed with bioelectrical impedance. Patients with cirrhosis often 
present carbohydrate, fat, and protein disorders, characterized by elevated levels of 
aromatic amino acids and methionine while lowering plasma levels of branched-chain 
amino acids are detected [81, 82]. The immediate postoperative energy demands are 
increased, especially in patients with a high MELD score [82]. Factors such as opera-
tional stress, release of catabolic hormones, administration of immunosuppressants, 
mainly corticosteroids, as well as ICU factors including mechanical ventilation and 
hemodialysis, contribute to increased metabolic needs. For the above reasons, the aim 
is to ensure adequate intake of protein and calories in addition to protein breakdown 
protection [81]. An increase in nonprotein calories, estimated at 25–35% kcal/kg per 
day, is recommended when indirect calorimetry is not available. It should always be 
in accordance with the metabolic and inflammatory status, and it should be reviewed 
in hemodynamically unstable patients [83]. Due to elevated protein catabolism, it is 
necessary to obtain 1.5–2 g/kg of protein. Enteral nutrition (EN) has the edge over the 
parenteral one, assisting in maintaining intestinal integrity, by supporting the diversity 
of the microbiome, and helping the immune and metabolic response. The rapid onset of 
EN even 12 h after LT is recommended by some authors. It has been reported to reduce 
viral infections and contribute to a better N2 balance. If postoperative encephalopathy 
remains, the amount of protein intake is not reduced but the type of nutrition is altered 
by the addition of branched-chain amino acid (BCCA) enriched formulae, while the 
administration of immunonutrition remains under discussion. Frequent screening of 
electrolytes is required to prevent and correct disorders, while re-feeding syndrome is 
also considered a risk factor for these disorders [83].
9. Renal dysfunction
Renal impairment is a very common complication after LT. Its presence ranges from 
19 to 64%. Even with the application of the RIFLE and AKIN criteria, the percentage 
reaches from 39 to 54% [84, 85]. In cases of living donors, acute kidney injury (AKI) 
has been estimated at around 23% [86]. AKI occurrence is complex and multifactorial 
in origin, depending on the existence of the preoperative hepatorenal syndrome as well 
as various intraoperative and postoperative factors. High MELD score, perioperative 
transfusions, hemodynamic instability, vasoactive agents, graft dysfunction, infec-
tions, and nephrotoxic agents are mainly accountable for renal function deterioration 
[87]. Systematic evaluation of renal function is required with close monitoring of urine 
output, fluid balance, and hemodynamic parameters [18]. The treatment is mainly 
supportive and includes: restoring CO with sufficient preload for optimization of renal 
perfusion, administering loop diuretics, and efforts to avoid nephrotoxic agents. Renal 
replacement therapy is recommended in cases of volume overload, electrolyte distur-
bances, and acidemia in an attempt to avoid pulmonary edema and hepatic congestion. 
Immunosuppressants, antibiotics, and contrast agents are commonplace nephrotoxic 
agents. The dosage of CNIs should be minimized or they should be converted into 
mTOR inhibitors combined with anti-proliferative agents. In ICU, CVVDHF is the renal 
replacement therapy of choice and favors the outcome of patients [88].
11
Management of Patients with Liver Transplantation in ICU
DOI: http://dx.doi.org/10.5772/intechopen.89435
10. Primary graft dysfunction
Primary graft dysfunction (PGD) is a major complication after LT and is associ-
ated with prolonged hospital and ICU stay jeopardizing graft viability, being respon-
sible for its high rejection rates as well as higher mortality and morbidity. It describes 
different degrees of graft impairment which begins intraoperatively, divided into 
early or initial poor function (IPF) and primary nonfunction (PNF) [89–91]. IPF 
represents the clinical phenotype of severe ischemia-reperfusion injury due to various 
donor and/or recipient-related factors. Expanding the criteria to marginal donors 
has increased the use of allografts with a higher likelihood of initial malfunction. 
It affects the survival of both graft and patient, whether the transplant comes from 
living or deceased donors. Dysfunction may be transient and possibly reversible with 
appropriate supportive treatment. There are no clear definitions, nevertheless, there 
are suggested scores, such as MEAF and LGrAFT, that could help in early detection 
and classification of early hepatic impairment [92, 93]. On the contrary, PNF is a 
catastrophic injury characterized by hepatic necrosis, aminotransferase elevation, 
coagulation disorders, lactate elevation, hemodynamic instability, persistent hypo-
glycemia, and respiratory and renal failure with an incidence ranging from 0.9 to 7%. 
The treatment is immediate re-transplantation. There are certain risk factors related 
to donors, recipients, intraoperative events, and allograft preservation [91] (Table 2).
11. Rejection
Acute cellular rejection (ACR), usually mediated by T-cells, has decreased in recent 
years with the use of improved potent immunosuppressants, but still ranges from 15 
to 25% and usually occurs 7–14 days after surgery [94]. Hyperacute liver rejection is 
controversial, but undoubtedly early accelerated rejection occurs in the first 7 days 
and is associated with preformed antibodies. Risk factors include adequacy, type, 
and level of immunosuppression, underlying immune disease, biliary complications, 
certain transplant-related features such as donor-negative recipient-positive CMV 
mismatch, sex mismatch with a female donor. ACR is not significantly associated with 
long-term graft failure unless it concerns HCV-positive patients in which case it may 
result in corticosteroid-resistant rejection and graft loss. Early ACR is associated with 
better graft outcomes [95]. It is even hypothesized that such activation of the immune 
system may be beneficial and may induce a degree of tolerance. Manifestations of ACR 
include elevated levels of aminotransferase, alkaline phosphatase, bilirubin, and fever 
in later stages. Hepatic artery or portal vein thrombosis, biliary leak, CMV infection, 
and delayed graft function should be excluded. Diagnosis is finally confirmed by 
percutaneous liver biopsy prior to initiation of treatment, which depends on patient 
severity and current immunosuppression [94]. Cyclosporine is converted to tacrolimus 
or the sub-therapeutic levels of tacrolimus are increased and/or mycophenolate mofetil 
is added. In moderate to severe ACR, high doses of corticosteroids, usually methyl-
prednizolone, are administered as a first-line medicine in a dose ranging from 500 to 
1000 mg for 1–3 days depending on the center protocol [94].
12. Cardiac complications after LT
Cirrhotic cardiomyopathy (CCM) is defined as cardiac dysfunction in patients 
with cirrhosis characterized by a blunted contractile responsiveness to stress and/
or diastolic dysfunction and electrophysiological abnormalities in the absence 
of known cardiac disease [96]. Diagnostic features include a reduced ejection 
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fraction (EF), an E/A ratio < 1, and electrocardiographic abnormalities such as a 
prolonged QTc interval. Diagnostic approaches involve transthoracic ultrasound, 
dobutamine stress echocardiography (DSE), as well as cardiac magnetic resonance 
(CMR). The concept of “ventriculo-arterial coupling” (VAC) has recently been sug-
gested as a means of assessing cardiac function in ESLD. The VAC (ratio of ventric-
ular elastance to arterial elastance) is measured conventionally by ultrasound and 
has been correlated with prognosis. Moreover, cardiac biomarkers such as troponin 
and brain natriuretic peptide (BNP) are deemed early markers [97].
It is difficult to define the exact impact of CCM due to the fact that its clinical 
course is usually silent, especially in early stages, due to the profound vasodilatation in 
cirrhosis and offloading of the left ventricle. It only becomes apparent in conditions of 
stress and increased afterload. LT is a cause of significant cardiovascular stress since 
there are marked variations in preload and afterload, cardiac workload increases and 
the existing underlying cardiac dysfunction may become overt heart failure during LT 
or several days postoperatively. Complete recovery has been recorded at 6 months [98].
Cardiac dysfunction and pulmonary edema are encountered in almost half of 
the patients within a week after LT. They have been identified as the third most 
important cause of mortality during the first year following the surgery. High 
MELD score and AKI have been considered as risk factors. Early diagnosis can 
prevent acute onset or deterioration of heart failure. An empirical and supportive 
therapeutic approach is applied which includes optimization of volume status and 
cardiac monitoring via echo and/or PAC [99, 100].
Prevalence of coronary artery disease (CAD) in cirrhosis reaches 5–26% and 
has been associated with poor prognosis. It has been correlated with a number of 
cardiac adverse events: myocardial infraction, arrhythmias, and cardiac death. 
LT can be postponed in cases with known CAD for medical optimization and/or 
revascularization [99, 100].
13. Neurological complications
Neurological complications (NC) are still common after LT with a 15–30% inci-
dence rate. In recipients from living donors, this percentage does not exceed 20% 
[101, 102]. Major neurologic complications immediately postoperatively include 
alterations of consciousness, seizures, hepatic encephalopathy, CNI neurotoxic-
ity, cerebrovascular complications, central nervous system infections, and central 
pontine myelinolysis (CPM) [103]. They can delay recovery and make immunosup-
pression and patient management difficult. Rapid patient recovery requires daily 
evaluation of mental status and neurological assessment in the ICU.
Immunosuppression-related neurotoxicity can range from headaches and con-
vulsions to posterior reversible encephalopathy (PRES). Immunosuppressants have 
the potential to reduce the seizure threshold that is enhanced by electrolytic disor-
ders mainly hypomagnesaemia and hypophosphatemia. CNIs are mainly implicated 
while incidents of PRES have been reported even in treatment with sirolimus. The 
treatment is conservative involving reduction of dosage and/or interchange with 
CNI-sparing regimens. Neurotoxicity of corticosteroids can be manifested either in 
the form of convulsions or myopathy and behavioral disorders [103].
Post-transplant encephalopathy is responsible for 12% of NC. It relates closely to 
metabolic disorders, CNS infections and/or septic encephalopathy, cerebrovascular 
events, history of severe encephalopathy, and graft dysfunction [78]. Seizures are one 
of the most common postoperative neurological consequences and may be the effect of 
various factors, mainly drug toxicity and metabolic disorders. Correction of underlying 
causes and administration of anti-convulsive medicines are the appropriate treatment.
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Central pontine myelinolysis (CPM) represents a serious complication, with a 
low incidence of approximately 1–3.5% that may affect the postoperative course of 
patients. It has been associated with large fluid shift and rapid correction of pro-
longed hyponatremia. The indicated treatment is supportive and requires careful 
correction of severe hyponatremia (serum Na <125 mEq/L), which is encountered 
in approximately 17% of patients with ESLD, using sodium chloride and adjusting 
Na serum values to 8–10 mEq/L per day [104, 105].
14. Ischemia reperfusion injury
Ischemia-reperfusion injury is related with the degree of transaminitis and 
primary and/or delayed graft dysfunction. Mitochondria are more prone to I/R 
injuries with subsequent alterations that can lead to dysfunction or even to necrosis 
of hepatocytes following LT. Alternatively, machine reperfusion has been proposed 
to preserve the donor organ. It promises to restore energy balance, extend preser-
vation time while offering the ability to “test” the organ performance [106, 107].
15. Postoperative surgical complications
15.1 Early surgical complications
In the early postoperative period, according to Parikh et al., 79.3% of patients are 
present with at least one complication with 62.8% of the recipients suffering severe 
Complications Diagnosis-treatment Therapeutic approach















Immediate surgical complications after LT.
Vascular complications Diagnosis Treatment





(endovascular or surgical) or re-LT





or surgical HA revision






Portal vein thrombosis (PVT)
5%
DUS, CT (portal phase)
Venography
Surgical revision
Endovascular intervention or re-LT
Portal vein stenosis (PVS)
2%




Vascular complications after LT.
Liver Disease and Surgery
14
Author details
Areti Karapanagiotou1,2*, Achillefs Pitsoulis2, Maria Vasileiou2  
and Nikolaos Voloudakis3
1 Intensive Care Unit “Hippokratio” Hospital, Thessaloniki, Greece
2 Intensive Care Unit “G. GENNHMATAS” Hospital, Thessaloniki, Greece
3 Second Surgical Department AUTH, Thessaloniki, Greece
*Address all correspondence to: aretikarapan@gmail.com
complications. The incidence of those related to surgical techniques range from 5 
to 10% and can be categorized into abdominal bleedings, vascular complications, 
and biliary complications. Treatment can be determined by the severity of each case 
and its spectrum includes simple surgical interventions, or even re-transplantation. 
The main complications are illustrated  in Tables 3 and 4 along with diagnostic and 
therapeutic approaches [108, 109].
16. Conclusions
LT has been established as the gold standard treatment for patients with ESLD 
and following successful postoperative course, organs previously affected return 
to normal functionality in due time. Postoperative ICU stay is often imperative, 
especially in cases of adverse events during operation, delayed cardiovascular 
resuscitation, utilization of marginal donors, and distant organ dysfunction. Early 
recognition, evaluation, and treatment of hemodynamic instability, distant organ 
complications, impaired graft functionality, and use of optimal immunosuppressive 
agents are of paramount importance.
Prompt recognition and treatment of life-threatening sequelae following LT in 
addition with optimal management of immunosuppression are keys to successful 
postoperative care and have led to improved overall survival although recipients are 
in relatively worse condition and the use of marginal donors is more widespread.
Furthermore, overall survival of LT patients has improved dramatically in recent 
years due to the formation of LT specific centers and medical teams, which follow 
each patient from admission to the donor list up to the operation itself as well as 
during their postoperative course. Therefore, according to the authors, the creation 
of LT specific ICUs that provide a postoperative continuation of excellency in 
managing the intricacies of those patients is paramount. Those units will not only 
provide prompt treatment in cases of a complication but will also act as additional 
reinforcement against postoperative infections.
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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